Verrica Pharmaceuticals Inc. (VRCA)

NASDAQ: VRCA · IEX Real-Time Price · USD
8.32 0.03 (0.36%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap228.96M
Revenue (ttm)12.00M
Net Income (ttm)-38.52M
Shares Out27.52M
EPS (ttm)-1.46
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume37,882
Open8.29
Previous Close8.29
Day's Range8.25 - 8.70
52-Week Range8.16 - 18.42
Beta2.04
AnalystsBuy
Price Target19.50 (+134.4%)
Earnings DateNov 15, 2021

About VRCA

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial for treating common warts; and that is in phase II clinical trial for the treatment of external genital warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agr...

IndustryPharmaceuticals
IPO DateJun 15, 2018
CEOTed White
Employees29
Stock ExchangeNASDAQ
Ticker SymbolVRCA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for VRCA stock is "Buy." The 12-month stock price forecast is 19.50, which is an increase of 134.38% from the latest price.

Price Target
$19.50
(134.38% upside)
Analyst Consensus: Buy

News

FDA Accepts Verrica's Resubmission For VP-102 For Contagious Skin Disease

The FDA has accepted Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) resubmitted marketing application seeking approval for VP-102 to treat molluscum contagiosum (molluscum), a common, highly contagious sk...

1 month ago - Benzinga

Verrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102 for the Treatment of Molluscum Con...

WEST CHESTER, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medica...

1 month ago - GlobeNewsWire

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Cont...

WEST CHESTER, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medica...

1 month ago - GlobeNewsWire

Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncol...

Company expects to initiate Phase 2 trial in basal cell carcinoma in 1Q 2022

1 month ago - GlobeNewsWire

Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results

Contract Manufacturer identified in prior CRL receives satisfactory resolution (VAI) of the facility's identified deficiencies from the FDA

2 months ago - GlobeNewsWire

Does Verrica Pharmaceuticals Inc. (VRCA) Have the Potential to Rally 60% as Wall Street Analysts Expect?

The mean of analysts' price targets for Verrica Pharmaceuticals Inc. (VRCA) points to a 59.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agree...

3 months ago - Zacks Investment Research

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Verrica Pharmaceuticals Inc. -VRCA

NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA).

3 months ago - PRNewsWire

Why Verrica Pharmaceuticals Stock Is Getting Pummeled Today

The Food and Drug Administration delivered some bad news regarding the company's dermatology candidate.

3 months ago - The Motley Fool

Why Verrica Pharmaceuticals Shares Are Trading Lower Today

Verrica Pharmaceuticals (NASDAQ:VRCA) shares are trading lower after the company announced the FDA issued a Complete Response Letter regarding its New Drug Application for VP-102 for the treatment of mo...

3 months ago - Benzinga

Verrica (VRCA) Gets CRL From the FDA for Skin Disease Drug

Verrica (VRCA) suffers a setback yet again as the FDA issues a CRL for its lead product candidate VP-102. Consequently, shares are trading down.

3 months ago - Zacks Investment Research

Verrica Pharma Shares Slide After Response Letter From FDA

The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) marketing application seeking approval for VP-102 for molluscum contagiosum, a highly contagiou...

3 months ago - Benzinga

Verrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Co...

No Specific Deficiencies Related to the Manufacturing of VP-102 Identified by FDA in its General Inspection of a Facility of the Contract Manufacturer

3 months ago - GlobeNewsWire

Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results

WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medica...

5 months ago - GlobeNewsWire

Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer

Company strengthens management team in anticipation of  the potential commercial launch of VP-102, if approved

6 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCA

New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA). Such inves...

7 months ago - Newsfile Corp

Verrica's (VRCA) Skin Disease Candidate Approval Gets Delayed

Verrica's (VRCA) NDA for lead candidate, VP-102, a drug-device combination treatment for skin disease, molluscum, is under review. FDA delays decision on potential approval for the candidate by three mo...

7 months ago - Zacks Investment Research

Verrica's VP-102 Application Review for Molluscum Contagiosum Delayed till September

The FDA has extended the review period for the marketing application for Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) VP-102 to treat molluscum contagiosum (molluscum). Now the Prescription Drug User Fe...

7 months ago - Benzinga

Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum...

– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to September 23, 2021 –

7 months ago - GlobeNewsWire

Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual Healthcare Conference

WEST CHESTER, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...

7 months ago - GlobeNewsWire

Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference

WEST CHESTER, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...

8 months ago - GlobeNewsWire

Verrica Pharmaceuticals Reports First Quarter 2021 Financial Results

– Expanded commercial team in preparation for potential FDA approval of VP-102 for the treatment of molluscum, which has been assigned a PDUFA goal date of June 23, 2021 –

8 months ago - GlobeNewsWire

Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

WEST CHESTER, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medic...

9 months ago - GlobeNewsWire

Verrica Announces Election of Gary Goldenberg, MD, Verrica's Chief Medical Officer, to Membership in the American Der...

WEST CHESTER, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...

9 months ago - GlobeNewsWire

Verrica Announces Pricing of Public Offering of Common Stock

WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...

9 months ago - GlobeNewsWire

Verrica Announces Proposed Public Offering of Common Stock

WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical intervent...

9 months ago - GlobeNewsWire